Hyperlipidemia
Episodes 1-16 of 35
- CME/CE Broadcast Replay
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
0.50 credits
Prof. Ulrich Laufs
Pam R. Taub, MD, FACC, FASPC
Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
Christie Ballantyne, MD
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Pam R. Taub, MD, FACC, FASPC
Prof. Kausik Ray
Daniel Gaudet, MD, PhD
- MinuteCE®
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
1.00 program creditBørge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Daniel Gaudet, MD, PhD
Pam R. Taub, MD, FACC, FASPC
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Daniel Gaudet, MD, PhD
Børge G. Nordestgaard, MD, DMSc
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Ira J. Goldberg, MD
Kausik Ray, MBChB, MD, MPhil
Christie Ballantyne, MD
- MinuteCE®
The remaining challenges in lowering LDL-c in patients at increased CV risk
0.75 program creditsProf. Kausik Ray
Ulrich Laufs, MD, PhD
- MinuteCE®
Clinical choices in managing LDL-c: Where do novel therapies fit in?
0.75 credits 4 episodesKausik Ray, MBChB, MD, MPhil
Julia Brandts, MD
Pasquale Perrone-Filardi, MD, PhD
Ulrich Laufs, MD, PhD
- Prev
- Next